logo-loader
RNS
BioPharma Credit PLC

NEW INVESTMENT OF UP TO US$50M IN CORMEDIX INC.

RNS Number : 4370C
BioPharma Credit PLC
10 November 2026
 

10 November 2026

  

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

NEW INVESTMENT OF UP TO US$50 MILLION IN CORMEDIX INC.

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, is pleased to announce that together with BioPharma Credit Investments V (Master) LP (“BioPharma-V”) it has entered into a new senior secured loan agreement (the “Loan Agreement”) with CorMedix Inc. (“CorMedix”).  The Company, through its fully owned subsidiary, will invest up to US$50 million and BioPharma-V will invest up to an additional US$100 million in parallel for a total US$150 million facility comprised of two tranches of US$75 million, with the Company acting as collateral agent.

 

On 9 November 2026, CorMedix announced entering into a definitive asset purchase agreement with Heron Therapeutics, Inc. (“Heron”), for the acquisition of substantially all of Heron’s assets (including four commercial-stage products: Zynrelef, Aponvie, Cinvanti, and Sustol).  The upfront consideration for the transaction is US$145 million in cash, subject to customary purchase price adjustments, 14,583,333 shares of CorMedix common stock, with additional consideration of up to US$55 million in earn-out payments to Heron with respect to 2028 Zynrelef net sales, and a royalty on net sales of certain products (the “Heron Acquisition”).  The Heron Acquisition is expected to close in Q1 2027, subject to regulatory clearance, approval by Heron stockholders, and other customary closing conditions.

 

Under the Loan Agreement, the Company will invest up to US$50 million across two tranches, with the balance of the tranches being provided by BioPharma-V, subject to customary conditions precedent:

  • Tranche A of US$25 million is available in connection with the closing of the Heron Acquisition; and
  • Tranche B of up to US$25 million is available to be requested until 30 June 2028, in connection with the in-licensing or acquisition of commercial-stage pharmaceutical products.

The loan will mature five years after the first funding date, and will bear interest at 3-month SOFR plus 5.75 per cent. per annum subject to a 3.50 per cent. SOFR floor. A one-time additional consideration of 1.50 per cent of each tranche is payable by CorMedix upon the funding of each respective tranche.  

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States, with a current market capitalization of ~US$418 million (Ticker: CRMD – NASDAQ).  CorMedix is focused on selling and marketing products in institutional care settings in the United States and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.  According to CorMedix, following the closing of the Heron Acquisition, it expects pro forma 2026 estimated revenue for the combined business of 12 commercial products to be US$465 million – US$490 million.

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZMGMMLKGVZZ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Director Declaration

1 week, 1 day ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 2 days ago

Dividend Declaration

on 09/30/2026

Holding(s) in Company

on 09/23/2026

Directorate change

on 09/15/2026

4 min read